

Clinical approach to respiratory tract infections (RTI) in non-neutropenic fever (NNF) children with cancer: lessons from identified cases during the mass religious gatherings and influenza seasons

Abstract

Background

No existing research has addressed respiratory tract illnesses (RTIs) in children with non-neutropenic fever (NNF) who present during the religious mass gatherings seasons (Hajj, Ramadan), especially if this coincides with influenza season. The treatment approach for RTI cases in NNF children during mass religious gatherings may not be applicable as in the normal season.

Methods:

This study involved a retrospective analysis of RTI in NNF children who presented during mass religious gathering seasons and/or flu season and who were being treated for malignancy at princess Noorah Oncology Center from May 01, 2016, through December 2017.

Results:

A total of 4599 spikes of fever were identified in 124 non-neutropenic children in whom 455 spikes (9.9%, 455 out of 4599) were documented during the mass religious gatherings and/or flu season. NNF secondary to RTIs was documented in 59.7% of patients during the study seasons with a total of 245 fever spikes recorded. Ceftriaxone-based therapy was the main treatment approach for NNF including the RTI cases that were associated with 50% of subsequent hospitalization for further management. Among all the examined risk factors, prolonged fever of more than three days was significantly associated with NNF secondary to RTI during mass religious gatherings if coincident with flu season, OR=0.034 [95% CI, 0.013 - 0.09] P-value <0.001.

Conclusions:

The present study showed that the prevalence rate of NNF of RTI in NNF children is increased during periods of mass gathering. There is a need for national consensus to address NNF management during mass religious gatherings particularly if coincident with flu season.

Introduction

Infection is the most common cause of treatment-related morbidity and mortality in children with cancer where the majority of the time fever is the only symptom of infection [1,2]. In the last 20 years, a couple of published studies found that almost half of the children with cancer develop at least one fever episode during the neutropenia phase (fever neutropenia) which is a common complication of chemotherapy treatment and respiratory tract infection among the predominant infection among neutropenic patients. While the frequency of non-neutropenic fever (NNF) episodes is scarce [3-5].

Respiratory tract infection (RTI) is well documented as one of the common causes of fever around the globe, especially during the influenza season subsequently causing significant delays in delivering cancer-specific therapy in up to 80% of children with cancer in the middle east, Europe, and Canada. However, the clinical presentation of respiratory infection in children with cancer compared to the general population is not specific [6-8]. During the 2009 influenza pandemic, more than 60% of children with cancer were diagnosed with influenza or influenza-like illness, of which 20% experienced severe symptoms that required hospitalization and further modification of their initial infection treatment course [9-12]. In September 2012, The Middle East respiratory syndrome coronavirus MERS-CoV was isolated in Saudi Arabia with few fatality cases reported in patients with cancer. The association of cancer with MERS-CoV-related fatality was uncertain [13-22].

The comprehensive care management for influenza infection includes the use of influenza vaccines and antiviral drugs which subsequently aid in planning the use of antibiotics and other treatment modalities. However, every flu season is different. The Saudi Arabia Ministry of Health (MOH) published its data in 2015 and stated that the influenza season in Saudi Arabia starts in September and ends in March every year in which the flu vaccine is offered in October annually [23].

The Hijri calendar also known in English as the Islamic calendar consists of 12 months similar to the Gregorian calendar. Mass religious gatherings follow the Arabic Hijri Calendar in which Ramadan is in month 9 and Dhul Hijja is in month 12. According to data from the Ministry of Haj and Umrah, the umrah season opens for nine months following the Hijri calendar (Safar, Rabi' Al-Awal, Rabi' Al-Thani, Jumada Al-Aula, Jumada Al-Thani, Rajab, Sha'ban, Ramadan, Shawal) while Hajj begins on the eighth day of Dhul Hijja and ends on the thirteenth day of the same Islamic month. Noteworthy, the kingdom of Saudi Arabia is the Custodian of the Two Holy Mosques (Al-Masjid al-Haram in Mecca city and Al-Masjid al-Nabawi in Medina city), considered the holiest in Islam. This attracts millions of Muslims from diverse geographical countries across the Muslim world to arrive in Jeddah, as it is the main gateway to the two holy cities especially during the months of Ramadan, or Hajj season annually, and/or to perform Umrah, which is allowed at any time around the year [24]. During these occasions of religious mass gatherings, the risk of transmitting respiratory illnesses, and introducing new pathogenic strains, or resistant organisms increases especially if this coincided with influenza (flu) seasons [25].

There are no existing reports addressing patients who present to hospital care with fever during the religious mass gatherings seasons especially if coincided with flu seasons and hence the treatment approach of such cases may not be applicable to patients with NNF in a normal season. With this

background, we conducted this study to determine the prevalence and clinical outcome of RTI in NNF children with cancer during major seasonal changes (mass gathering and flu season).

Materials & Methods

This is a retrospective secondary analysis of our previous study aimed to evaluate the prevalence of RTIs in NNF children with cancer.

All Children aged 0 to less than 15 years who were treated for malignancy at princess Noorah Oncology Center (PNOC)-King Abdulaziz Medical City (KAMC)-Jeddah, Saudi Arabia from May 01, 2016, through December 2017 were eligible.

We followed the same analysis and methodology for collecting the missing data as in our previously published paper [3]. We used the same chart review method for data collection, definition, classification, and data analysis as per our previously published study.

Definition

- Fever is defined as two spikes of temperature more than 38° Celsius orally for over 30 minutes or at least 38.3° Celsius orally for over one hour
- Non-Neutropenia episode is defined as a hospital visit with an absolute neutrophil count (ANC) $\geq 500 /\mu\text{l}$
- Respiratory tract infection (RTI) is an infectious process of the respiratory tract and can include both upper respiratory tract infection (URTI) or/and lower respiratory tract infection (LRTI) [26].
 - URTI include common cold, laryngitis, pharyngitis/tonsillitis, acute rhinitis, acute rhinosinusitis, and acute otitis media
 - LRTI includes acute bronchitis, bronchiolitis, pneumonia, and tracheitis
 - If the patient presented with both symptoms of URTI and LRTI, they were classified as LRTI
- Children were classified as well appearing if the child was active, tolerating good oral intake, with no obvious focus of infection, abnormal exam, or hemodynamic instability such as unexplained tachycardia, tachypnea, desaturation, and hypotension. These patient were treated empirically by antibiotics in the outpatient setting with daily clinic follow-up until they will be a febrile for two consecutive days.
- Patients were admitted to hospital care if they did not meet the well-appearing criteria (i.e. lethargic, hypoactive, hypotensive, irritable, dehydrated, has decreased oral intake, or has prolonged duration of fever beyond 72 hours despite outpatient management)
- Diagnoses were classified using the International Classification of Childhood Cancer (ICCC) -O-3/WHO 2010 and grouped as lymphoma/ leukemia, neuroblastoma (NBL), brain tumor, and other tumor diagnoses [27].

Inclusion and exclusion criteria

Subjects were eligible for inclusion if had at least one documented spike of fever at a presentation during mass religious gathering seasons (Hajj, Ramadan) and/or flu season.

Exclusion criteria:

- No respiratory symptoms indicating RTI
- Presented with a clear clinical focus of infection other than RTI during physical examination
- Cancer patients with underlying primary immunodeficiency
- Hematopoietic stem cell transplant recipients on active immunosuppression therapy
- Patients with Down's syndrome
- Patients on active chemotherapy with their neutrophil count expected to decline to less than 500 / μ l in the next 48 hours

Outcome measures

- Failure of primary treatment option determined by
 - Number of fever spikes
 - Numbers of patients needing subsequent therapy (antibiotic modification and/or hospitalization)
- The prevalence rate of RTI in patients with NNF

Comparing RTI rate during major seasons (mass religious gatherings and influenza seasons vs normal seasons).

In order to avoid the biases of misclassification and to overcome missing data, we applied the same methodology for measuring or evaluating the treatment outcomes during the study period of mass religious gatherings and flu season versus normal season

Data analysis

Descriptive statistics was done to summarize the demographic and baseline clinical characteristics using numbers and percentages in categorical data and means and standard deviations for continuous data if the data were normally distributed, while medians and quartiles were used if the data were not normally distributed. Comparison between categorical data was done using chi-square statistics while a t-test was used to compare continuous with categorical data. Logistic regression analysis was conducted to examine the association of RTI with mass gathering in subjects with FNN after controlling for potential confounders. The odds ratio (OR) was used as a measure of this association with its 95% confidence interval (CI). All data were entered and analyzed through the statistical package SPSS 25 software (SPSS Inc., Chicago, IL, USA)

Results

During the 20 months study period, A total of 480 non-neutropenic fever (NNF) episodes were identified in 131 children. Among these 131, 42 NNF children with a total of 136 NNF episodes presented during religious mass gatherings (28 during Ramadan, 10 during Hajj, and 4 during Hajj concurrent with Flu season), and 89 NNF children with a total of 344 NNF episodes presented during Umrah season (35 during normal Umrah season and 54 during Umrah coincident with Flu season).

Among the 131 NNF children, 76 patients had respiratory tract infection symptoms (43 were RTI and had 4599 spikes of fever (92.4%). Of the 4599 spikes of fever, 455 spikes (9.9%) were documented during mass religious gatherings and flu season. The overall rate of NNF spikes during mass religious gatherings was 5% (233 out of 4599), during flu season was 3.4% (156 out of 4599), and during mass gathering coincidence with flu season was 1.4% (66 out of 4599) (Figure 1).

The mean age of the patients was 6.4 ± 3.4 years and 60.5% of the patients were male. A majority (71.8%) of the patient had a central venous catheter (CVC) implanted. Using the International Classification of Childhood Cancer (ICCC) -O-3/WHO 2010 the majority of the patients had leukemias, myeloproliferative diseases, & myelodysplastic diseases (66.9%). Table 1 summarizes patients' basic demographic data

The prevalence of RTIs and patient characteristics

The prevalence of RTIs was 59.7% (74 out of 124) with a total of 245 fever spikes (245 out of 455, 53.8%). The mean temperature was 38.52°C with $\text{SD} \pm 0.56$ with a mean CRP level ($\pm \text{SD}$) of $32.9 (\pm 47.9)$ mmol/L. Using the ICCC for diagnosis, the majority of the patients had leukemia (67.9%).

URTI was the most documented symptom in 87.8% (34 out of 74, 45.9% presented during the mass religious gathering (20 patients during Ramadan and 14 patients during Hajj) and 30 out of 74, (88.2%) presented during the flu season). Cough, sore throat, and runny nose were the most common presenting symptoms of URTI (29 out of 74, 39.2 %). Table 2 summarizes the demographic data of patients with fever presented with RTI during the study period

Patient characteristics and outcomes during a mass religious gathering

The RTIs rates; A total of 34 NNF patients presented during the mass religious gatherings (20 patients during Ramadan and 14 patients during Hajj). The vast majority of the patients (26 out of 34, 76.5%) had an implanted central venous catheter (CVC). More than 80% (29 out of 34, 85.3%) of patients presented with URTI, followed by 8.8% (3 out of 34) who had mixed symptoms of URTI and LRTI, and only 5.9% (2 out of 34) of patients had LRTI (one patient during Ramadan and one patient during Hajj).

Table 3 summarizes the patients characteristics presenting with respiratory tract infection (RTI) during the religious mass gatherings.

Failure of primary treatment option

The total number of fever spikes recorded was 114 (64 spikes during Ramadan and 50 spikes during Hajj). None of the cases developed any microbiological positive culture.

Ceftriaxone-based therapy plus or minus oral macrolide (azithromycin or clarithromycin) was the main treatment approach for the majority of cases (76.5%, 26 out of 34), followed by oral macrolide in addition to one of the beta-lactam antibiotics (14.7%, 5 out of 34), two patients (5.9 %, 2 out of 34) treated with piperacillin-tazobactam plus gentamicin, and one patient (2.9 %, 1 out of 34) treated with second-line antibiotics (meropenem in addition to vancomycin). Median days to fever resolution after starting antibiotics were 1 day (IQR 1-4) and the median duration of antibiotics use was 5 days (IQR 5-7). Out of 34 patients, 22 patients (64.7%) needed hospitalization. All of them (100%) had implanted CVC. The total documented spikes of fever were 68 with a maximum of 40-Celsius \pm 0.66. Causes of hospital admission were decreased oral intake (1), lethargy (1), query relapse (1), prolonged fever (12), and persistent RTI symptoms despite fever resolution (7). None of the included cases needed intensive care (ICU) admission and there was no case fatality associated with RTI.

Patient's characteristics and outcomes during flu season

The RTIs rates; A total of 30 NNF patients presented during flu season. Majority of patients presented with URTI (26 out of 30, 86.7%). More than 60% of the patients had implanted CVC (19 out of 30). The total recorded number of recorded fever spikes was 91 (maximum fever was 41-Celsius with \pm 0.66). None of the cases developed any microbiological positive culture. Table 4 summarizes the patients characteristics presenting with respiratory tract infection (RTI) during flu season.

Failure of primary treatment option

Ceftriaxone monotherapy was the main treatment approach for the majority of the cases (60%, 18 out of 30). Modification of initial treatment was noted in 40% of patients (12 out of 30) as follows: oral clarithromycin or augmentin or IV vancomycin was added to ceftriaxone in 16.7% of patients (5 out of 30), five patients (16.7%, 5 out of 30) received oral antibiotic only with augment (2), penicillin (1), ciprofloxacin (1), and azithromycin (1). Two patients were treated with piperacillin-tazobactam plus gentamicin (6.6%, 2 out of 30). Median days to fever resolution after starting antibiotics were 1.5 days (IQR 1-4) and the median duration of antibiotics use was similar to the median duration of antibiotic use during the mass gathering was 5 days (IQR 5-7). Out of 30 patients, 11 patients (36.7%) needed hospitalization. Only one of them had no CVC.

The total documented spikes of fever were 32 with a maximum of 39.1-Celsius \pm 0.69. Causes of hospital admission were decreasing oral intake (1), prolonged fever (3), and Fever resolved but symptoms persist (7).

NNF cases during mass religious gatherings coinciding with flu season

Of note, 10 out of 74 patients (13.5%) presented with fever secondary to RTIs during the mass religious gatherings (mainly Hajj) that coincided with flu season. The vast majority of patients had CVC implanted (60%, 6 out of 10). The total documented spike of fever was 40 with a maximum of 39.5-Celsius \pm 0.53.

Table 5 summarizes the patients characteristics presenting with respiratory tract infection (RTI) during the religious mass gatherings co-incidence with flu season

Ceftriaxone was the main treatment approach used in 90% (9 out of 10 patients). Of those, two patients received oral azithromycin in addition to ceftriaxone. Only one (10%) dehydrated looks unwell child patient received piperacillin-tazobactam in addition to vancomycin. Four patients needed subsequent hospitalization with a mean CRP level of 52.6 ± 58.2 . The mean reasons for hospitalization were dehydration (1), prolonged fever (1), and no fever but RTI symptoms persist (2).

Anti-viral or flu vaccine

None of the included patients received the prophylactic flu vaccine for flu season and none of the patients who presented with RTI received oral antiviral (oseltamivir).

Cases with documented respiratory viral or bacterial infections

None of the clinically documented cases had microbiologically confirmed viral or bacterial infections

Discussion

In this study, RTI is quite prevalent in NNF children with cancer. RTI was recognized in nearly 60% of NNF episodes. To our knowledge, no previous studies have addressed RTI in children with cancer who presented with fever and non-neutropenia during religious mass gatherings or flu season. The majority of the published studies focused on respiratory viral infection in children with fever neutropenia (FN) [28-30]. Although in the current study we didn't identify any respiratory pathogen in all included cases, which does not rule out respiratory viral infections, however, it may co-exist with other pathogens [31].

The influenza pandemic is an unpredictable viral disease that can cause severe complications and result in hospitalization and death [32]. Children with cancer are special cases that are highly susceptible to developing severe infections by different respiratory viral pathogens including influenza (flu) [1,6,31, 32]. We have reported a previously high failure rate of using ceftriaxone mono-therapy in children with NNF and almost 43% of them presented with respiratory symptoms [3]. Of note, in the current study, none of our included cases received a prophylactic flu vaccine and none of them received antiviral therapy during their treatment course. Additionally, mass gatherings, especially if coincided with flu season, might be responsible for the RTI prevalence rates. Different approaches in managing such cases during important and special occasions or seasons may result in a delay in delivering appropriate therapy, inappropriate use of broad antimicrobials, treatment failure, missed important clinical findings, and result in re-admission or prolong hospitalization.

The United States Advisory Committee on Immunization Practices (ACIP) published updated guidelines in 2020 and they recommend using inactivated influenza vaccine for a variety of patient populations who are at increased risk of complications from influenza including immunosuppressed patients (including immunosuppression caused by medications) [32]. It is a reality that there is neither clear national data about the seasonality of different influenza strains nor the burden and impact of influenza infection or respiratory viral illness in children with cancer diseases.

Nowadays, people around the globe are facing a novel coronavirus named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the International Committee on Taxonomy of Viruses (ICTV) causing coronavirus disease 2019 (COVID-19). The novelty of the SARS-CoV-2, is that it quickly spread from Wuhan, China to other countries around the globe. The typical signs and symptoms range from mild to moderate such as fever, dry cough, dyspnea, fatigue, severe pneumonia, or even death [33-36]. At the time of writing this paper, no identified evidence-based treatment is readily available for use in pediatrics with cancer [37,38]. Of note, the first COVID-19 disease case caused by SARS-CoV-2 in Saudi Arabia was identified on March 2, 2020 [39].

Future studies looking at withholding unnecessary antibiotics use in children NNF with respiratory viral infections based on diagnostic microbiological and/or molecular results are highly suggested. This approach is particularly important since Jeddah city is year-round the main gateway to the two holy cities (Makkah and Madinah) during religious mass gathering season (Ramadan, and Hajj), and if coincident with flu season the risk of viral infection may be higher.

The results of our study are important in the current COVID-19 pandemic. During this time the Saudi government took on initiatives to reduce mass gatherings including holding all visits to Makah and Medina in addition to different measures of social distancing. These measures are important particularly in our region as the present study showed that the rate/prevalence of NNF secondary to RTI in children with cancer is increased during periods of mass gathering.

Major study limitations include the lack of national data on FNN during flu season and religious mass gathering incidence and approach. The retrospective nature of the study limited access to certain important information such as testing of respiratory pathogens. In addition, this is a single institution study that represents a small number of patients.

Larger, multi-organization nationwide studies should be conducted in the future to corroborate our findings. Ultimately, we believe a national consensus guideline aiming to standardize the clinical approach to NNF children with a suspected respiratory viral infection, providing evidence, sound effective antiviral therapy guide, and limiting unnecessary broad-spectrum antibiotics in this vulnerable patient population.

Conclusion

Children with cancer are vulnerable to respiratory infections due to their chronic illness even if they are non-neutropenic, especially during major seasonality occasions (religious mass gatherings and flu season). RTI symptoms are associated with a prolonged period of fever, and days of antibiotic use and result in subsequent hospitalization. Proactively implementing a surveillance program to ensure proper vaccination, early screening of virus during the season, proper education to patients, and their families regarding appropriate infection control measures, and proper personal protection during major seasonal changes will help optimize their management.

References

1. Lehrnbecher T, Laws HJ: [Infectious complications in pediatric cancer patients](#). *Klin Padiatr.* 2005, 1:3-8. [10.1055/s-2005-872498](#)
2. O'Connor D, Bate J, Wade R: [Infection-related mortality in children with acute lymphoblastic leukemia: a retrospective analysis of infectious deaths on](#). *UKALL.* 20032014, 124:1056-62. [10.1182/blood-2014-03-560847](#)
3. AlAzmi A, Jastaniah W, AlDabbagh M, Elimam N: [A clinical approach to non-neutropenic fever in children with cancer \[published online ahead of print, 2020 May 31\]](#). *J Oncol Pharm Pract.* 2020, 1078155220925161:[10.1177/1078155220925161](#)
4. Ammann, R. A., Tissing, W. J. & Phillips, B: [Rationalizing the approach to children with fever in neutropenia](#). *Curr Opin Infect Dis.* 2012, 25:258-265. [10.1097/QCO.0b013e328351d199](#)
5. Zoe Allaway, Robert S. Phillips, Karin A. Thursky and Gabrielle M: [Haeusler, Nonneutropenic fever in children with cancer: A scoping review of management and outcome](#), *Pediatric Blood & Cancer*, 66, 6. 2019. [10.1002/psc.27634](#)
6. Lindblom A, Bhadri V, Söderhäll S, et al.: [Respiratory viruses, a common microbiological finding in neutropenic children with fever](#). *J Clin Virol.* 2010, 47:234-7. [10.1016/j.jcv.2009.11.026](#)
7. Täger FM, Zolezzi RP, Folatre BI, Navarrete CM, Rojas PJ: [Respiratory virus infections in children with acute lymphoblastic leukemia and febrile neutropenia: A prospective study](#). *Rev Chilena Infectol.* 2006, 23:118-23. [10.4103/abr.abr_433_15](#)
8. Mendoza Sanchez MC, Ruiz-Contreras J, Vivanco JL, et al.: [Respiratory virus infections in children with cancer or HIV infection](#). *J Pediatr Hematol Oncol.* 2006, 28:154-159. [10.1007/s40121-017-0160-3](#)
9. Tran D, Science M, Dix D, et al.: [Pandemic \(H1N1\) 2009 influenza in Canadian pediatric cancer and hematopoietic stem cell transplant patients](#). *Influenza Other Respi Viruses.* 2012, 6:105-113. [10.1111/j.1750-2659.2012.00352.x](#)
10. Seiter K, Shah D, Sandoval C, et al.: [Prospective evaluation of 2009 H1N1 influenza A in patients admitted with fever to an oncology unit](#). *Infect Control Hosp Epidemiol.* 2011, 32:815-7. [10.1086/661105](#)
11. Caselli D, Carraro F, Castagnola E, et al.: [Morbidity of pandemic H1N1 influenza in children with cancer](#). *Pediatr Blood Cancer.* 2010, 55:226-8. [10.1002/psc.22619](#)
12. Tasian SK, Park JR, Martin ET, et al.: [Influenza-associated morbidity in children with cancer](#). *Pediatr Blood Cancer.* 2008, 50:983-987. [10.1002/psc.21472](#)
13. Zaki AM, van Boheemen S, Bestebroer TM, et al.: [Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia](#). *N Engl J Med.* 367:1814-1820. [10.1056/NEJMoa1211721](#)
14. Balkhy HH, Alenazi TH, Alshamrani MM, et al.: [Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia](#). *Infect Control Hosp Epidemiol.* 37:1147-1155. [10.1017/ice.2016.132](#)
15. Jazieh AR, Alenazi TH, Alhejazi A, et al.: [Outcome of Oncology Patients Infected With Coronavirus](#). *JCO Glob Oncol.* 2020, 6:471-475. [10.1200/GO.20.00064](#)
16. Assiri A., Abedi G.R., Saeed A.A.B., et al.: [Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia](#). *Emerg Infect Dis.* 2016, 22:32-40. [10.3201/eid2201.151370](#)
17. Assiri A, McGeer A, Perl T M, et al.: [Hospital outbreak of Middle East respiratory syndrome coronavirus](#). *N Engl J Med.* 2013, 369:407-416. [10.1056/NEJMoa1306742](#)
18. Memish Z.A., Cotton M., Watson S.J., et al.: [Community case cluster of Middle East respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study](#). *Int J Infect Dis.* 2014, 23:63-68. [10.1128/JVI.01244-13](#)
19. Noorwali A.A., Turkistani A.M., Asiri S.I., et al.: [Descriptive epidemiology and characteristics of confirmed cases of Middle East respiratory syndrome coronavirus infection in the Makkah Region of Saudi Arabia, March to June 2014](#). *Ann Saudi Med.* 2015, 35:203-209. [10.5144/0256-4947.2015.203](#)

20. Assiri A., Al-Tawfiq J.A., Al-Rabeeh A.A., et al.: [Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study](#). Lancet Infect Dis. 2013, 13:752-761. [10.1016/S1473-3099\(13\)70204-4](#)
21. Aleanizy FS, Mohamed N, Alqahtani FY, et al.: [Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study](#). BMC Infect Dis. 2017:23-2017. [10.1186/s12879-016-2137-3](#)
22. Al-Tawfiq JA, Hinedi K, Ghandour J, et al.: [Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients](#). Clin Infect Dis. 2014, 59:160-5. [10.1093/cid/ciu226](#)
23. [Ministry of Health \(MOH\). Influenza Surveillance in Saudi Arabia](#). Accessed: November 5, 2021: <https://www.moh.gov.sa/CCC/healthp/regulations/Documents/ISSA%20Protocol.pdf>.
24. Ministry of hajj and:22-2021.
25. Benkouiten S, Charrel R, Belhouchat K, et al.: [Respiratory viruses and bacteria among pilgrims during the 2013 Hajj](#). Emerg Infect Dis. 2014, 20:1821-1827. [10.3201/eid2011.140600](#)
26. [Centre for Clinical Practice at NICE \(UK\). Respiratory Tract Infections - Antibiotic Prescribing: Prescribing of Antibiotics for Self-Limiting Respiratory Tract Infections in Adults and Children in Primary Care](#). London: National Institute for Health and Clinical Excellence (UK; 2008)69.
27. [International Classification for Childhood Cancer \(ICCC\)](#). Accessed October 10, (2021). <https://seer.cancer.gov/iccc/iccc-who2008.html>.
28. Srinivasan A, Zhengming G, Smith T, et al.: [Prospective detection of respiratory pathogens in symptomatic children with cancer](#). Pediatr Infect Dis J. 2013, 32:99-104. [10.1097/INF.0b013e31827bd619](#)
29. Söderman M, Rhedin S, Tolfvenstam T, et al.: [Frequent respiratory viral infections in children with febrile neutropenia-a prospective follow-up study](#). PLoS One.2016. 11:0157398. [10.1371/journal.pone.0157398](#)
30. Benites EC, Cabrini DP, Silva AC, et al.: [Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy](#). J Pediatr (Rio J. 2014, 90:370-376. [10.1016/j.jped.2014.01.006](#)
31. Torres JP, Labraña Y, Ibañez C, et al.: [Frequency and clinical outcome of respiratory viral infections and mixed viral-bacterial infections in children with cancer, fever and neutropenia](#). Pediatr Infect Dis J. 2012, 31:889-893. [10.1097/INF.0b013e31825c4b7e](#)
32. Grohskopf LA, Alyanak E, Broder KR, et al.: [Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020-21 Influenza Season](#). MMWR Recomm Rep. 2020;69, 8:1-24.
33. [SARS \(Severe Acute Respiratory Syndrome\). World Health Organization \(WHO\)](#). Accessed: July 20, 2020: <https://www.who.int/ith/diseases/sars/en/>.
34. Wang D, Hu B, Hu C, et al.: [Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China](#). JAMA. 2020, 323:1061-1069. [10.1001/jama.2020.1585](#)
35. Huang C, Wang Y, Li X, et al.: [Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China](#). Lancet. 2020, 395:497-506. [10.1016/S0140-6736\(20\)30183-5](#)
36. Barry M, Al Amri M, Memish ZA: [COVID-19 in the Shadows of MERS-CoV in the Kingdom of Saudi Arabia](#). J Epidemiol Glob Health. 2020, 10:1-3. [10.2991/jegh.k.200218.003](#)
37. [Naming the coronavirus disease \(COVID-19\) and the virus that causes it. World Health Organization \(WHO\) available at](#). Accessed: July 20, 2020: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease--an...>
38. (192020). Accessed: July 20, 2020: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
39. [Saudi Arabia reports first coronavirus case](#). Accessed: July 20, 2020: <http://saudigazette.com.sa/article/590136>.

**TABLE 1:
BASIC DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF INCLUDED NNF CASES**

| VARIABLES | N=124 |
|--|-----------------|
| GENDER (%) | |
| MALE | 75 (60.5) |
| FEMALE | 49 (39.5) |
| MEDIAN AGE IN YEAR ± SD | 6.4 ±3.4 |
| LOCATION OF PRELIMINARY TREATMENT (%) | |
| OUTPATIENT WITH FOLLOW UP | 116 (93.5) |
| INPATIENT | 8 (6.5) |
| DIAGNOSIS (%) | |
| LEUKEMIAS, MYELOPROLIFERATIVE DISEASES, & MYELOYDYSPLASTIC DISEASES | 83 (66.9) |
| RENAL TUMORS | 8 (6.5) |
| NEUROBLASTOMA & OTHER PERIPHERAL NERVOUS CELL TUMORS | 7 (5.6) |
| CNS & MISCELLANEOUS INTRACRANIAL & INTRASPINAL NEOPLASMS | 5 (4) |
| SOFT TISSUE AND OTHER EXTRAOSSEOUS SARCOMAS | 4 (3.2) |
| MALIGNANT BONE TUMORS | 4 (3.2) |
| OTHER & UNSPECIFIED MALIGNANT NEOPLASMS | 3 (2.4) |
| GERM CELL TUMORS, TROPHOBLASTIC TUMORS, AND NEOPLASMS OF GONADS | 3 (2.4) |
| LYMPHOMAS & RETICULOENDOTHELIAL NEOPLASMS | 2 (1.6) |
| HEPATIC TUMORS | 2 (1.6) |
| INTRACRANIAL & INTRASPINAL EMBRYONAL TUMORS | 2 (1.6) |
| SOFT TISSUE & OTHER EXTRAOSSEOUS SARCOMAS | 1 (0.8) |
| CVC (%) | |
| CENTRAL LINE | 89 (71.8) |
| PERIPHERAL LINE | 35(28.2) |
| MEAN TEMPERATURE °C ±SD | 38.5 (0.57) |
| MEDIAN ABSOLUTE NEUTROPHIL COUNT (IQR) | 3.4 (1.9 – 5.7) |
| RELIGIOUS MASS GATHERING SEASONS (%) | |
| RAMADAN | 40 (32.3) |
| HAJJ | 26 (20.9) |
| COINCIDENCE FLU SEASON WITH HAJJ (%) | 14 (11.3) |
| FLU SEASON (%) | 44 (35.5) |
| NNF CASES PRESENTED WITH RTI (%) | |
| YES | 74 (59.7) |
| NEED SUBSEQUENT HOSPITALIZATION | 37 (50%) |
| NO | 50 (40.3) |
| TOTAL NUMBER OF FEVER EPISODES N, (%) | 455 |
| MASS GATHERING AND FLU SEASON | 154 (33.8) |

N: Number; SD, Standard Deviation; RTI, Respiratory Tract Infection; CVC, Central Venous Catheter; IQR, Interquartile Range; NNF, Non-Neutropenic Fever

UNDER PEER REVIEW

Table 2
Characteristics of RTI cases presented with fever during major seasonal occasions (N= 245 Fever)

| Number of Fever episodes N=245, (%) | | Mass gathering, No Flu | Flu season No mass gathering | Flu season coincident with mass gathering |
|-------------------------------------|------------------|---------------------------|---------------------------------|--|
| | | 114 (46.5) | 91 (37.2) | 40 (16.3) |
| Gender | Male | 74 | 48 | 22 |
| | Female | 40 | 43 | 18 |
| Age | ≤ 6 year | 76 | 49 | 7 |
| | 6.1 – 12 year | 37 | 39 | 31 |
| | > 12 | 1 | 3 | 2 |
| Fever days | <3 days | 67 | 60 | 28 |
| | 3-7 days | 47 | 29 | 12 |
| | > 7 days | 0 | 0 | 2 |
| Chemo Phase | Consolidation | 35 | 5 | 3 |
| | Maintenance | 45 | 49 | 34 |
| | Off chemotherapy | 34 | 37 | 3 |

Table 3:

Characteristics of NNF cases presented with respiratory tract infection (RTI) during religious mass gatherings

| Variables | N=34 |
|--|--------------------------|
| Gender (%) | |
| <i>Male</i> | 20 (58.8) |
| <i>Female</i> | 14 (41.2) |
| Median Age in year (IQR) | 6 (3-8.85) |
| PHASE OF CHEMOTHERAPY TREATMENT (N) | |
| <i>INDUCTION</i> | 0 |
| <i>CONSOLIDATION</i> | 11 |
| <i>MAINTENANCE</i> | 13 |
| <i>OFF-TREATMENT</i> | 12 |
| RTI types (%) | |
| <i>URTI</i> | 29 (85.3) |
| <i>LRTI</i> | 2 (5.9) |
| <i>Mixed</i> | 3 (8.8) |
| CVC (%) | |
| <i>Central</i> | 26 (76.5) |
| <i>Peripheral</i> | 8 (23.5) |
| Religious Mass gathering season (%) | |
| <i>Ramadan</i> | 20 (58.8) |
| <i>Hajj</i> | 14 (41.2) |
| Location of preliminary treatment (%) | |
| <i>Outpatient with follow up</i> | 31 (91.1) |
| <i>Need Subsequent Hospitalization</i> | 22 (64.7%, 22 out of 31) |
| <i>Inpatient</i> | 3 (8.8) |
| Total Number of Fever episodes N, (%) | N=114 |
| <i>Ramadan</i> | 64 (56.1) |
| <i>Hajj</i> | 50 (43.9) |

N: Number; SD, Standard Deviation; RTI, Respiratory Tract Infection; CVC, Central Venues Catheter; IQR, Interquartile Range; NNF, Non-Neuropenic Fever

TABLE 4.
CHARACTERISTICS OF NNF CASES PRESENTED WITH RESPIRATORY TRACT INFECTION (RTI) DURING
FLU SEASON

| VARIABLES | N=30 |
|--|------------|
| GENDER (%) | |
| MALE | 14 (46.7) |
| FEMALE | 16 (53.3) |
| MEDIAN AGE IN YEAR (IQR) | 7 (4.25-8) |
| PHASE OF CHEMOTHERAPY TREATMENT (N) | |
| INDUCTION | 0 |
| CONSOLIDATION | 3 |
| MAINTENANCE | 14 |
| OFF-TREATMENT | 13 |
| RTI TYPES (%) | |
| URTI | 26 (86.7) |
| LRTI | 4 (13.3) |
| MIXED | 0 |
| CVC, (%) | |
| CENTRAL | 19 (63.3) |
| PERIPHERAL | 11 (36.7) |
| LOCATION OF PRELIMINARY TREATMENT (%) | |
| OUTPATIENT WITH FOLLOW UP | 26 (86.7) |
| NEED SUBSEQUENT HOSPITALIZATION | 11 |
| INPATIENT | 4 (13.3) |
| TOTAL NUMBER OF FEVER EPISODES (N) | N=91 |

N: Number; SD, Standard Deviation; RTI, Respiratory Tract Infection; CVC, *Central Venues Catheter*; IQR, *Interquartile Range*; NNF, *Non-Neuropenic Fever*

TABLE 5.
CHARACTERISTICS OF NNF CASES PRESENTED WITH RESPIRATORY TRACT INFECTION (RTI) DURING
MASS RELIGIOUS GATHERING CO-INCIDENCE WITH FLU SEASON

| VARIABLE | N=10 (%) |
|--|---------------|
| GENDER (%) | |
| <i>MALE</i> | 6 (60%) |
| <i>FEMALE</i> | 4 (40%) |
| MEDIAN AGE IN YEAR (IQR) | 8 (7.25-9.75) |
| PHASE OF CHEMOTHERAPY TREATMENT (%) | |
| <i>INDUCTION</i> | 0 |
| <i>CONSOLIDATION</i> | 2 (20%) |
| <i>MAINTENANCE</i> | 7 (70%) |
| <i>OFF-TREATMENT</i> | 1 (10%) |
| RTI TYPES (%) | |
| <i>URTI</i> | 8 (80%) |
| <i>LRTI</i> | 2 (20%) |
| <i>MIXED</i> | 0 |
| CVC, (%) | |
| <i>CENTRAL</i> | 6 (60%) |
| <i>PERIPHERAL</i> | 4 (40%) |
| LOCATION OF PRELIMINARY TREATMENT (%) | |
| <i>OUTPATIENT WITH FOLLOW UP</i> | 9 (90%) |
| <i>NEED SUBSEQUENT HOSPITALIZATION</i> | 4 |
| <i>INPATIENT</i> | 1 (10%) |
| TOTAL NUMBER OF FEVER EPISODES (N) | N=40 |

N: Number; SD, Standard Deviation; RTI, Respiratory Tract Infection; CVC, *Central Venues Catheter*; IQR, *Interquartile Range*; NNF, *Non-Neurogenic*

Fever




Figure 1. Overall rate of fever spikes in NNF children with cancer in relation to Total documented fever spikes over study period (May 2016 to December 2017)

UNDER REVIEW

UNDER PEER REVIEW